Caribou Biosciences, Inc. announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for CB-012, an allogeneic anti-C-type lectin- like molecule-1 (anti-CLL-1) CAR-T cell therapy. CB-012 will be evaluated in the multicenter, open-label, AMpLify Phase 1 clinical trial for patients with relapsed or refractory acute myeloid leukemia (r/r AML).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.845 USD | -1.22% | -5.48% | -50.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.35% | 257M | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.95% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |
- Stock Market
- Equities
- CRBU Stock
- News Caribou Biosciences, Inc.
- Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia